tbuckley/cabot-search huggingface dataset:
Abstract 293: More Nursing Care Increases In-Hospital Cardiac Arrest Survival
Authors: Monica F Rochman, Beatrice J Kalisch
Journal: Circulation (2013)

The objective of this study was to investigate the association between shift level nurse staffing, and survival to discharge for patients sustaining an in-hospital cardiac arrest (IHCA). In many instances, the most likely first responder to witness IHCA and provide needed treatment is the registered nurse. Delays in treatment are associated with decreased survival; every minute is important during cardiac arrest. Little if any comprehensive research has been undertaken to determine the features of nursing that are important in the outcomes of cardiac arrest, however. Thus, there is a critical need to thoroughly examine if and how nursing affects survival patients experiencing in-hospital cardiac arrest. This study was a cross sectional secondary analysis of an in-hospital cardiac arrest registry and staffing data obtained from hospital productivity reports. Registered nurse hours per patient day were analyzed during the nursing shift that the cardiac arrest occurred. Generalized estimating equation models were used account for the clustering of patients within units. The sample consisted of adult patients aged 18 and older who sustained an in hospital cardiac arrest between May 2004 and December 2009 in one Mid-western academic hospital. The final analytic sample consisted of 299 patients in 22 medical surgical, rehabilitation and intensive care units. One additional hour per patient day of RN care results in 19% greater odds of surviving to discharge while controlling for patient and unit characteristics in the model. Shift- level staffing measured at the time of the event was found to positively predict in-hospital cardiac arrest survival. The findings from this study will serve to inform nursing practice with regard to the importance of staffing levels which can impact survival. Response times to cardiac arrests depend on recognizing the arrest and the ability to respond and provide treatment in a timely manner. This is directly the result of the availability of staff to react to such a situation. Moreover, a closer perspective in examination of a specific event and shift-level staffing, the more likely important process improvement initiatives will be appropriate and successful.
Senior Adult Oncology, Version 2.2014
Authors: Arti Hurria, Tanya Wildes, Sarah L. Blair, Ilene S. Browner, Harvey Jay Cohen, Mollie deShazo, Efrat Dotan, Barish H. Edil, Martine Extermann, Apar Kishor P. Ganti, Holly M. Holmes, Reshma Jagsi, Mohana B. Karlekar, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Hope S. Rugo, Randall W. Rupper, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Alva B. Weir, Mary Anne Bergman, Hema Sundar
Journal: Journal of the National Comprehensive Cancer Network (2014)

Cancer is the leading cause of death in older adults aged 60 to 79 years. The biology of certain cancers and responsiveness to therapy changes with the patient's age. Advanced age alone should not preclude the use of effective treatment that could improve quality of life or extend meaningful survival. The challenge of managing older patients with cancer is to assess whether the expected benefits of treatment are superior to the risk in a population with decreased life expectancy and decreased tolerance to stress. These guidelines provide an approach to decision-making in older cancer patients based on comprehensive geriatric assessment and also include disease specific issues related to age in the management of some cancer types in older adults.
춘계학술대회 발표 : 포스터전시 ; SPIO 조영증강 자기공명영상에서 간실질의 신호강도 감소의 원인: 간종양과 혼동할 수 있는 소견
Authors: 최준일, 홍은경, 박중원, 김창민, 박상재, 이우진, 김성훈, 김태현, 김현범, 한성식
Journal: Clinical and Molecular Hepatology (2006)
Long-Term Survivors of Advanced Neuroblastoma With <i>MYCN</i> Amplification: A Report of 19 Patients Surviving Disease-Free for More Than 66 Months
Authors: K. Kawa, N. Ohnuma, M. Kaneko, K. Yamamoto, T. Etoh, H. Mugishima, M. Ohhira, J. Yokoyama, F. Bessho, T. Honna, J. Yoshizawa, K. Nakada, M. Iwafuchi, T. Nozaki, J. Mimaya, T. Sawada, T. Nakamura, H. Miyata, K. Yamato, Y. Tsuchida
Journal: Journal of Clinical Oncology (1999)

PURPOSE: According to initial reports, stage 4 neuroblastoma patients with amplification of the MYCN proto-oncogene developed progressive disease within 8 months. The prognosis for such patients, however, should now be reevaluated in light of recent results achieved with up-to-date combination chemotherapy. PATIENTS AND METHODS: Patients with stage 3, 4, and 4S neuroblastoma and more than 10 copies of MYCN received induction chemotherapy, which from January 1985 to February 1991 consisted of regimen A 1 (cyclophosphamide 1,200 mg/m 2 on day 1, vincristine 1.5 mg/m 2 on day 1, pirarubicin 40 mg/m 2 on day 3, and cisplatin 90 mg/m 2 on day 5) and from March 1991 to September 1993 consisted of regimen A 3 (cyclophosphamide 1,200 mg/m 2 on days 1 and 2, pirarubicin 40 mg/m 2 on day 3, etoposide 100 mg/m 2 on days 1 through 5, and continuous infusion cisplatin 25 mg/m 2 on days 1 through 5). Most of these patients underwent radical surgery to remove the original tumor and local metastases, irradiation, and supralethal preconditioning regimens, followed by blood stem-cell transplantation (SCT). Data on the patients were collected in December 1998, and the factors contributing to disease-free survival were analyzed. RESULTS: During the study period, 66 patients with more than 10 copies of MYCN were treated. Five of nine patients with stage 3 disease, 13 of 55 with stage 4, and one of two with stage 4S survived for at least 66 months. It is interesting that all but one patient who survived for more than 66 months underwent SCT, in contrast with only five of 45 patients who died. CONCLUSION: Not all patients with advanced neuroblastoma who have more than 10 copies of MYCN will die. The requisites for survival in such patients seem to be intensive induction chemotherapy, effective surgery, irradiation, and the use of SCT.
Vinorelbine—gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial
Authors: G. Krajnik, A. Mohn-Staudner, J. Thaler, R. Greil, S. Schmeikal, F. Marhold, J. Deutsch, P. Preiss, R. Malayeri, C. Schäfer-Prokop, W. Wein, H. Huber, R. Pirker
Journal: Annals of Oncology (2000)
Large deletion of the 5' end of the ROMK1 gene causes antenatal Bartter syndrome.
Authors: D Feldmann, J L Alessandri, G Deschênes
Journal: Journal of the American Society of Nephrology (1998)

Mutations in exon 5 of the ROMK1 gene (KCNJ1) have recently been observed in antenatal Bartter syndrome patients. This study describes a homozygous deletion removing KCNJ1 exons 1 and 2 observed in a consanguineous family with antenatal Bartter syndrome. Absence of the untranslated exon 1 led to the deletion of transcription elements located in this exon that may cause the disease. Deletion of exon 1 transcription elements should lead to the absence of hROMK2-K5 transcripts, whereas hROMK1 transcripts should normally be transcripted. Consequently, probably only hROMK2-K5 transcripts are expressed in the medullary thick ascending limb of Henle.
Moderate aerobic exercise training attenuates inflammatory response to streptococus pneumoniae in mice
Authors: Clarice Olivo, Maria Leonor Oliveira, Eliane Miyagi, Francine Almeida, Petra Arantes, Paulo Ho, Fernanda Lopes, Milton Martins
Journal: European Respiratory Journal (2011)

Streptococus pneumoniae  is one of the most important causes of morbidity and mortality in respiratory diseases. Aerobic exercise is known to attenuate inflammatory processes in some lung injuries.   Objectives:  To study if moderate exercise training prior to bacterial infection alters the pulmonary inflammatory profile.   Methods:  40 Balb/C mice (14-16 weeks) were divided into 4 groups: Control (C), Aerobic Exercise (AE),  S. pneumonia  infection (P),  S. pneumonia  + Aerobic Exercise (P+AE). Moderate intensity treadmill training was performed over 4 weeks, 5 time/wk, 60 min/session in the AE and P+AE groups. After 72 hs of the last exercise training session, P and P+AE groups were challenged intranasally with pneumococcal strains M10 (type 11A) through the inoculation of 50 μl of the suspension of the bacteria in 0.9% saline. C group did not receive intranasal instillation or exercise training. Bronchoalveolar lavage (BAL) was performed 10 days after the intranasal challenge to quantify the number of total cells, macrophages, neutrophils and lymphocytes.   Results:  S. pneumonia  inoculation resulted in increase number of total cells (18.63×10 4 cels/mL ± 9.02; p 4 cels/mL ± 1.94; p 4 cels/mL ± 6.84; p S. pneumonia  inoculated animals resulted in significantly decrease in total number of cells (10.15×10 4 cels/mL ± 1.10; p 4 cels/mL ± 0.84; p=0.003) in BAL.   Conclusion:  These results suggest that moderate aerobic exercise training attenuated the neutrophilic inflammation in an animal model of bacterial infection.Supported by FAPESP, LIMHC-FMUSP, CNPq, Brazil.
Reply to Matthew Bultitude and Pieter Le Roux's Letter to the Editor re: Jens Sønksen, Neil J. Barber, Mark J. Speakman, et al. Prospective, Randomized, Multinational Study of Prostatic Urethral Lift Versus Transurethral Resection of the Prostate: 12-month Results from the BPH6 Study. Eur Urol 2015;68:643–52
Authors: Jens Sønksen, Christian Gratzke
Journal: European Urology (2015)
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia
Authors: Dirk Bassler, Richard Plavka, Eric S. Shinwell, Mikko Hallman, Pierre-Henri Jarreau, Virgilio Carnielli, Johannes N. Van den Anker, Christoph Meisner, Corinna Engel, Matthias Schwab, Henry L. Halliday, Christian F. Poets
Journal: New England Journal of Medicine (2015)

Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infants, but they may compromise brain development. The effects of inhaled glucocorticoids on outcomes in these infants are unclear.
Abstract 350: Early Cell-Cell Coupling Contributes to Loss of Transplanted Stem Cell Retention and Efficacy
Authors: Santipongse Chatchavalvanich, David L Geenen
Journal: Circulation Research (2012)

Bone marrow-derived mesenchymal stem cell (BM-MSC) replacement therapy is beneficial to the heart following ischemia but a significant loss of these cells within hours of administration could diminish their effect. We hypothesized that early coupling between BM-MSC and ischemic cardiomyocytes through gap junctions (GJ) may play a detrimental role in stem cell survival and retention in the acute phase of cell therapy. We seeded HL-1 cardiomyocytes in either normoxic (Nx) or ischemic (Isc) conditions for four hours. Subsequently, BM-MSC were seeded on the HL-1 monolayer and the co-cultures were returned to incubation either in their previous conditions (Nx, Isc) or switched from Isc to Nx condition (ischemia-reperfusion; Isc/Rep) for an additional two hours. Co-cultures were labeled with Annexin V, Sytox Red, and Sca-1 (BM-MSC), and subjected to flow cytometry. Ischemia induced a greater proportion of dead BM-MSC over the two-hour co-culture compared to the Nx group. Isc/Rep resulted in significantly higher early apoptotic but fewer dead BM-MSC. The presence of the GJ inhibitor carbenoxolone (CBX; 100 µM) in the co-culture reduced the number of dead and apoptotic cells in Isc and Isc/Rep groups by 3-5 fold (p&lt;0.05). To determine the effect of GJ inhibition in vivo, we induced ischemia in mice by 90-minute LAD ligation followed by reperfusion for 24 hours. BM-MSC, CBX-treated BM-MSC, or CBX alone were injected at the end of the 90 min Isc period. Twenty-four hours after cell injection, left ventricular diastolic and systolic function was assessed by pressure-volume loop analysis. Isc/Rep caused impaired cardiac function which was attenuated by BM-MSC injection. CBX-treated BM-MSC further enhanced the cardiac function (MSC vs. MSC+CBX: Ees 7.3 ± 1.66 vs. 15.0 ± 5.81; Emax 18.8 ± 6.50 vs. 27.5 ± 9.33; PRSW 49.5 ± 9.89 vs. 99.4 ± 17.4; mean ± SD; p≤0.05; n = 6) while CBX alone did not. While long term integration of stem cells within the myocardium relies on functional GJ, early GJ communication may represent a novel paradigm whereby ischemic cardiomyocytes cause a “bystander effect” in newly transplanted stem cells and thus impair retention and functional benefits.
Clinicopathologic characteristics of patients who underwent additional gastrectomy after incomplete endoscopic resection for early gastric cancer.
Authors: Jae Jin Hwang, Dong Ho Lee, Ae-Ra Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim
Journal: Journal of Clinical Oncology (2015)

39 Background: Endoscopic resection (ER) is widely accepted as standard treatment for early gastric cancer (EGC) without lymph node metastasis. However, surgery is sometimes needed after endoscopic mucosal resection (EMR)/endoscopic submucosal dissection (ESD) due to incomplete resection. We analyzed the clinicopathological characteristics of patients who underwent additional gastrectomy after incomplete EMR/ESD. Methods: From 2003 to 2013, 80 patients received additional gastrectomy after EMR/ESD due to incomplete resection. The patients were grouped according to the presence of histologic residual tumor in specimens obtained by gastrectomy as residual tumor (RT, n = 47) or non-residual tumor (NRT, n = 33). We analyzed reasons for gastrectomy, tumor characteristics of RT and NRT group, risk factors associated with residual tumor, retrospectively from medical records. Results: After the gastrectomy, the positive residual tumor rate and lymph node metastasis rate were 58.7% (47/80) and 7.5% (6/80). RT group showed significantly higher rate of lateral and vertical margin involvement compared to NRT group (59.5 vs. 15.1%).Multivariate analysis demonstrated that endoscopic piecemeal resection, H. pylori infection, depressed or mixed type, large tumor size (&gt; 2cm), histologic diagnosis (signet ring cell carcinoma or mixed carcinoma) were significantly independent predictive factors associated with positive residual tumor of patients who underwent additional gastrectomy after incomplete EMR/ESD (p &lt; 0.05). Conclusions: For complete and curative ER, endoscopists should try to determine the depth of invasion, histologic diagnosis accurately and to eradicate the H. pylori infection before ER. During ER, wide marking and En bloc resection could be considered to avoid the risk of incomplete resection.
The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy
Authors: V. Rudat, M. Münter, D. Rades, K. Grötz, U. Haberkorn, W. Brenner, D. Jürgen
Journal: Journal of Clinical Oncology (2005)

5502 Background: In this study, two approaches to preserve the parotid function after radiotherapy are compared: Application of the radioprotective agent Amifostine during radiotherapy and Intensity-Modulated Radiotherapy (IMRT) to reduce the parotid radiation dose. Methods: Patients were qualified for this study if (1) both parotid glands received a radiation dose of at least 50 Gy using conventional radiotherapy techniques or if they received a parotid sparing IMRT as alternative, if (2) a salivary gland scintigraphy before radiotherapy (RT) and at least one after RT was performed, and if (3) a normal parotid function was present before RT. As measure for the parotid gland function the mean of the maximal tracer uptake (ΔU) of both glands was used. Results: Altogether 237 salivary gland scintigraphies of 88 patients were analysed. At 1–12 months after RT, an ANOVA with post-hoc comparison using the Bonferroni correction showed a significant difference between the IMRT and the conventional RT (p<0.0001) or Amifostine group (p<0.001). The difference between the Amifostine and conventional RT group was not significant (p=0.48). At 13–45 months after RT, the difference between the Amifostine and conventional RT group was significant (p<0.01). Conclusion: Amifostine and IMRT are both able to partially preserve the parotid function after radiotherapy. The effect of IMRT is much stronger. No significant financial relationships to disclose.
Hepatitis-Associated Antigen and Antibody in Hepatocellular Carcinoma: Results of a Continuing Study&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Charles L. Vogel
 4, Peter P. Anthony, F. Sadikali, Lewellys F. Barker, Michael R. Peterson
Journal: JNCI Journal of the National Cancer Institute (1972)

Tests for hepatitis-associated antigen (HAA) and antibody to HAA (anti-HAA) were done on sera from 90 Ugandan patients with hepatocellular carcinoma and 224 controls. While the frequency of anti-HAA did not differ between the 2 groups, the frequency of persistent HAA infection was significantly greater in the hepatocellular carcinoma patients than in controls. Alpha fetoprotein (AFP)-positive patients with hepatocellular carcinoma were HAA positive significantly more often than AFP-negative patients. Although the etiologic implications of these findings are speculative, the data support the hypothesis that viral hepatitis infection is a factor in the ultimate development of hepatocellular carcinoma in Ugandan patients.
Detection and Quantitation of Macrophage Infiltration Into Primary Human Tumors With the Use of Cell-Surface Markers 2
Authors: Gary W. Wood, Katherine A. Gollahon
Journal: JNCI Journal of the National Cancer Institute (1977)

The present study was designed to determine the presence of Fc receptor-positive cells within a series of primary nonlymphoreticular human neoplasms and to characterize them as to type. Frozen sections from 39 tumors of various histopathologic types were evaluated both qualitatively and quantitatively for Fc receptor activity by adsorption of antibody-coated sheep erythrocytes (EA). The quantity of EA adsorption varied from less than 5 to 100% of the tumor section covered. Positive sections exhibited two patterns of adsorption: focal and diffuse. Evaluation of sections exhibiting focal patterns indicated that the areas where tumor cells were concentrated failed to adsorb EA. Nevertheless, in many of the tumors, the admixture of tumor cells and Fc receptor-positive cells was significant. Of the tumors, 22 were digested enzymatically and their cell content was assessed. In each of the derived tumor cell suspensions, fewer than 5% of the cells were morphologically identifiable as lymphocytes. Similarly, morphologic analysis demonstrated few granulocytes in 20 of 22 tumors. Moreover, the percentage of Fc receptor-positive cells in the suspensions varied from 2 to 56. The Fc receptor-positive cells were characterized by nonspecific esterase staining, phagocytosis, and morphology as greater than 95% macrophages. The number of Fc receptor-positive cells in the suspensions correlated well with the degree of EA adsorption to tumor sections. Thus clearly many primary human neoplasms included in this study were infiltrated by significant numbers of macrophages.
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.
Authors: S Welt, C R Divgi, N Kemeny, R D Finn, A M Scott, M Graham, J S Germain, E C Richards, S M Larson, H F Oettgen
Journal: Journal of Clinical Oncology (1996)

A phase I/II study was designed to determine the maximum-tolerated dose (MTD) of iodine 131-labeled monoclonal antibody (mAb) A33 (131I-mAb A33) administered intravenously, its limiting organ toxicity, and its radioisotope retention in tumors, and to develop preliminary evidence of antitumor activity.Patients (N = 23) with colorectal cancer who had failed to respond to conventional chemotherapy but had not received prior radiotherapy were treated with escalating doses of 131I-mAb A33. Three or more patients were entered at each dose level, starting at 30 mCi/m2, with increments of 15 mCi/m2 to a maximal dose of 90 mCi/m2. Radiolabeling was performed to maintain a specific activity of 30 mCi/m2/4 mg mAb A33 (projected maximum, 15 mCi/mg). Patients were under strict isolation precautions until whole-body radiation levels decreased to less than 5 mrem/h at 1 m. Serial radioimmunoscintigrams were performed in some cases for up to 3 weeks after 131I-mAb A33 administration.All 20 patients with radiologic evidence of disease showed localization of radioisotope to sites of disease. Two patients with elevated carcinoembryonic antigen (CEA) levels and negative radiologic tests did not have positive antibody scans. One patient with a small-bowel cancer also had a negative antibody scan. The major toxicity was hematologic and was more pronounced in patients with compromised bone marrow due to prior chemotherapy. Of five patients who received 78 to 84 mCi/m2 131I-mAb A33, one had grade 3 and one grade 4 toxicity; of six patients treated with 86 to 94 mCi/m2 131I-mAb A33, two had grade 4 and one grade 1 toxicity. The MTD was determined to be 75 mCi/m2 in these heavily pretreated patients. Although the isotope showed variable uptake in the normal bowel, gastrointestinal symptoms were mild (n = 8) or absent. No major responses were observed; however, three patients had evidence of mixed responses, and CEA levels decreased in two patients without clinical or radiologic measurable disease. Immunoreactivity of radiolabeled mAb A33 decreased at the highest dose levels in preparations in which specific activity exceeded 18 mCi/mg.The A33 antigen appears to be a promising target for radioimmunotherapy of colon cancer. The modest antitumor activity of 131I-mAb A33 in heavily pretreated patients is encouraging because of its lack of toxicity in the bowel, the only antigen-positive normal tissue.
Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer.
Authors: S E Jones, R G Mennel, B Brooks, M A Westrick, M A Allison, R S Paulson, K Tilmann, B Rea
Journal: Journal of Clinical Oncology (1991)

A new combination of mitoxantrone, folinic acid (leucovorin), and infusional fluorouracil (5-FU) was administered to 57 previously treated patients with metastatic breast cancer to evaluate the response rate, response duration, and toxicity of this regimen. Fifty-three patients who received 313 courses of therapy were assessable for response and toxicity. Median age was 48 years (range, 33 to 80 years), and the patients had received an average of 1.5 chemotherapy regimens before this study. Of 53 assessable patients, 24 (45%, or 42% of all entered patients) experienced partial responses (PRs) with a median duration of 6 months (range, 2 to 13 months). Nine (69%) of 13 assessable patients without prior doxorubicin treatment responded, compared with 15 (38%) of 40 with prior doxorubicin (P less than .05). Toxicity was generally mild with dose reductions necessitated more often by mucositis and/or diarrhea than by myelosuppression. One patient with prior high-dose doxorubicin treatment developed congestive heart failure. The combination of mitoxantrone, leucovorin, and infusional 5-FU is an active and well-tolerated regimen for metastatic breast cancer and deserves further evaluation in patients without prior doxorubicin therapy.
P-029 Neuroendocrine tumors (NETs): response to chemotherapy by histological grade – experience cneter
Authors: C. Gonzalez-Rivas, L. Castillo, E. Gonzalez-Flores, L. Ochoa, J. Ruiz-Vozmediano, V. Amezcua, C. Sanchez-Toro, J. Garcia-Garcia, J.R. Delgado
Journal: Annals of Oncology (2015)